Smart Add-On for inhalers a hero for people with COPD and asthma?

Aptar Pharma unveiled a new connected device that could turn standard metered-dose inhalers into smart connected devices. HeroTracker Sense was developed to help patients around the world suffering from chronic respiratory diseases such as asthma, COPD, cystic fibrosis and other respiratory conditions caused by COVID-19 by promoting inhalation technique and l patient compliance.

Designed to attach to an inhaler cartridge, HeroTracker Sense uses sensors that support coordination of inspiration with actuation, rate and duration of inhalation. The BreatheSmart app features time stamps to indicate when patients should take their medications as well as environmental monitoring alerts on temperature and humidity, Aptar Pharma reported in a press release.

“The launch of HeroTracker Sense positions Aptar’s digital respiratory portfolio as a world-leading offering, providing insights into patient behaviors and how this will lead to a change in how the patient interacts with their device and understanding of its indication. We see this as a product for the future and one that will demonstrate significant value, creating concrete evidence that can help support reimbursement models in many different markets,” explained Marcus Bates, Director, Business Development, Digital Health, Aptar Pharma, in the version.

HeroTracker Sense can also provide healthcare providers with valuable patient training, onboarding and performance insights and analytics through the Aptar Pharma Cohero Health BreatheSmart Connect portal, which is both HIPAA and HIPAA compliant. GDPR, the company reported.

“HeroTracker Sense is a strategic addition to Aptar’s portfolio of digital health solutions in the respiratory space, and underscores Aptar Pharma’s advancements in digital therapeutics, as well as our commitment to providing tools that will lead to improvement in the lives of patients. commented Sai Shankar, President, Digital Health, Aptar Pharma.

HeroTracker Sense was designed and developed using Aptar Digital Health’s ISO 13485 certified quality management system; it is CE marked and is pending FDA approval.

In 2020, Aptar Pharma worked with Lupine Limited on Adhero, which would be India’s first “connected device” for metered-dose inhalers. Adhero attaches to the top of an inhaler.

Aptar Pharma has also been active in nasal drug delivery, providing its single-dose powder system for rescue treatment of severe hypoglycemia and delivery technology for NARCAN (naloxone HCl) nasal spray.